



Dr. Vinay Ch MD (Pathology & Chairman & Cor				m Chopra D (Pathology) ht Pathologist	
NAME	: Mrs. URMIL YADAV				
AGE/ GENDER	: 72 YRS/FEMALE	P	ATIENT ID	: 1666359	
COLLECTED BY	: SURJESH	R	EG. NO./LAB NO.	: 012411090040	
REFERRED BY		REGISTRATION DATE		: 09/Nov/2024 12:17 PM	
BARCODE NO. : 01520429		COLLECTION DATE		:09/Nov/2024 12:22PM	
LIENT CODE. : KOS DIAGNOSTIC LAB		REPORTING DATE		: 09/Nov/2024 01:21PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
	CLINI	CAL CHEMIST	RY/BIOCHEMIST	RY	
	Chitte	LIPID PROF			
רוחו בגדבסטו ייטי	TAL · SEDIM	283.28 ^H	mg/dL	OPTIMAL: < 200.0	
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP		283.28"	ing/uL	BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR =	
				240.0	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		147.19	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0	
				VERY HIGH: $> OR = 500.0$	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		65.16	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		188.68 ^H	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0	
NON HDL CHOLES by CALCULATED, SPE		218.12 ^H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0	
VI DI CUOI ESTEDA	JI · SEDIIM	29.44	ma/di	VERY HIGH: > OR = 220.0 0.00 - 45.00	
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		29.44	mg/dL	0.00 - 43.00	
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		713.75 ^H	mg/dL	350.00 - 700.00	
		4.35	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0	



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab:6349/1, Nicholson Road, Ambala Cantt -133 001, HaryanaKOS Molecular Lab:IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana0171-2643898, +91 99910 43898care@koshealthcare.comwww.koshealthcare.comwww.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist								
NAME	: Mrs. URMIL YADAV							
AGE/ GENDER	: 72 YRS/FEMALE	PAT	ENT ID	: 1666359				
COLLECTED BY	: SURJESH	REG.	NO./LAB NO.	: 012411090040				
REFERRED BY :		REG	STRATION DATE	: 09/Nov/2024 12:17 PM				
BARCODE NO.	: 01520429		LECTION DATE	: 09/Nov/2024 12:22PM				
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REP	ORTING DATE	: 09/Nov/2024 01:21PM				
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT							
Test Name		Value	Unit	Biological Reference interval				
LDL/HDL RATIO: SERUM by Calculated, spectrophotometry		2.9	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0				
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		2.26 ^L	RATIO	3.00 - 5.00				

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

